Association of Baseline Spinal Cord Area and Brain Volume With Long-Term Disability Progression in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis: Final Analysis From the DAYBREAK Open-label Extension Study

被引:0
|
作者
Filippi, Massimo [1 ,2 ]
Henry, Roland [3 ]
Arnold, Douglas [4 ,5 ]
Granziera, Cristina [6 ,7 ,8 ,9 ,10 ,11 ,12 ,13 ,14 ]
Kappos, Ludwig [9 ,10 ,11 ,12 ,13 ,14 ]
Sheffield, James [15 ]
Cheng, Chun-Yen [15 ]
Riolo, Jon [15 ]
Pachai, Chahin [15 ]
Cree, Bruce A. C. [3 ]
机构
[1] IRCCS San Raffaele Sci Inst, Neurol Unit, Div Neurosci, Neuroimaging Res Unit,Neurorehabil Unit, Milan, Italy
[2] Univ Vita Salute San Raffaele, Neurophysiol Serv, Milan, Italy
[3] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA
[4] McGill Univ, NeuroRx Res, Montreal, PQ, Canada
[5] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada
[6] Univ Hosp Basel, Dept Biomed Engn, Translat Imaging Neurol ThINk Basel, Fac Med, Basel, Switzerland
[7] Univ Basel, Basel, Switzerland
[8] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[9] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[10] Univ Hosp, Dept Headorgans Spine & Neuromed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[11] Univ Hosp, Dept Clin Res, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[12] Univ Hosp, Dept Biomed, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[13] Univ Hosp, Dept Biomed Engn, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland
[14] Univ Basel, Basel, Switzerland
[15] Bristol Myers Squibb, Princeton, NJ USA
关键词
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
P1451/510
引用
收藏
页码:922 / 923
页数:2
相关论文
共 43 条
  • [41] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
    Wolinsky, Jerry S.
    Arnold, Douglas L.
    Brochet, Bruno
    Hartung, Hans-Peter
    Montalban, Xavier
    Naismith, Robert T.
    Manfrini, Marianna
    Overell, James
    Koendgen, Harold
    Sauter, Annette
    Bennett, Iain
    Hubeaux, Stanislas
    Kappos, Ludwig
    Hauser, Stephen L.
    LANCET NEUROLOGY, 2020, 19 (12): : 998 - 1009
  • [42] Long-term efficacy, safety, and tolerability of three-times weekly dosing regimen of glatiramer acetate in relapsing-remitting multiple sclerosis patients: 5-year results of the Glatiramer Acetate Low-Frequency Administration (GALA) open-label extension study
    Alexander, Jessica
    Beygi, Hooman
    Feldman, Peter
    Ashtamker, Natalia
    NEUROLOGY, 2018, 90
  • [43] Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the random-ised, placebo-controlled, phase 3 trial (vol 19, pg 998, 2020)
    Wolinsky, J. S.
    Arnold, D. L.
    Brochet, B.
    LANCET NEUROLOGY, 2021, 20 (01): : E1 - E1